1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
628B0A45235ED301265258416003EF3F2
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-advocacy-2020-technology-use-current-trends-future-directions-5562?opendocument
18
19opendocument
2035.173.234.140
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Patient Advocacy

Patient Advocacy 2020: Use of Technology, Current Trends & Future Directions

ID: 5562


Features:

21 Info Graphics

4 Data Graphics

50+ Metrics

7 Narratives


Pages/Slides: 33


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Patient Advocacy 2020: Use of Technology, Current Trends & Future Directions”

STUDY OVERVIEW

Technological advancements have opened new information pathways for pharma and patient advocacy groups. The platforms used to deliver patient education play an important role in the reach and effectiveness of advocacy groups' programs and, by extension, help identify which patient organizations are best for pharma to collaborate with.

Best Practices, LLC undertook benchmarking research to identify current and emerging trends in patient advocacy. This study also delivers benchmarks around effective platforms for delivering education to patient groups, and contains a chapter with qualitative data from respondents regarding current trends in the advocacy space.

KEY TOPICS

  • Understanding the “advocacy” landscape
  • Effective platforms to deliver education to patient groups
  • Current issues surrounding patient advocacy
  • Future directions

KEY METRICS
  • What current factors in the marketplace do you feel should receive the greatest consideration with respect to patient advocacy issues?
  • Please rate the importance of the listed platforms in delivering education to patient groups

SAMPLE KEY FINDINGS
  • New technologies for patient education: Video sites, social networks, professional networks, and podcasts have created new channels and opportunities for internal and external advocacy groups to educate patients. This study reveals that 80% of participants rated social network groups like Facebook as important. Likewise, 78% rated YouTube and other video sites as important.

METHODOLOGY

Best Practices, LLC engaged 74 leaders supporting patient advocacy at 61 biopharmaceutical companies through a benchmarking survey. More than 60% of participants are at the director/ senior director level. Nearly 65% of participants are from the United States.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Communications; Medical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Clinical Research; Research; Health Care; Laboratories


Companies Profiled:
AbbVie; Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; ApotheCom; Astellas; AveXis; AVROBIO; Baldwin Area Medical Center; Bayer; Biogen; BioMarin; Bionical Emas; Blue Earth Diagnostics; Bluebird Bio; Boehringer Ingelheim; Covance; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Forum Pharmaceuticals; Grifols; GlaxoSmithKline ; Genzyme; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Lundbeck; Mallinckrodt; Merck; Milestone Pharmaceuticals; MSD; Natera; NexGen Healthcare Communications; Novartis; Novo Nordisk; OTSUKA; Parkway Pantai; Pfizer; Pharmacyclics; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Sanofi; Servier; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Theravance; Tillotts Pharma; UCB Pharma; Ultragenyx; Wave Life Sciences; Zimmer Biomet; Zogenix; The Mexican Organization for Rare Disorders (OMER)

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.